BRAF and neoplasm: In vivo studies to target BRAF mediated signaling in other tumor types as well as first clinical trials in pediatric oncology have highlighted the importance of combination treatment targeting BRAF driven signaling (3, 4), one of such potential additional targets is the fibroblast growth factor receptor 1 (FGFR1).